# ChemoCentryx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chemocentryx

- Industry: Biotechnology
- Headquarters: San Carlos, US
- Website: www.chemocentryx.com
- Total disclosed funding: $48M
- Latest round: Series D (Mar 22, 2007)
- Investors on record: 7

## About

ChemoCentryx, Inc. is a biotechnology company focused on developing innovative therapeutics for serious diseases through its expertise in chemokine biology. Its commitment lies in advancing treatments that target severe conditions.ChemoCentryx, Inc. was founded in 1997 in San Carlos, US. The company specializes in developing therapies aimed at addressing unmet medical needs in severe diseases. Founded by Thomas Schall, who has a history of founding other companies, ChemoCentryx has raised a total of USD 45.00 mn through its IPO, marking a significant milestone in its funding journey. The company has completed a total of 9 deals to date.ChemoCentryx is primarily known for its development of targeted therapies aimed at treating autoimmune diseases, cancer, and inflammatory conditions. Its lead product candidates are designed to inhibit chemokine receptors, which play a crucial role in disease progression. The company's offerings are geared towards improving patient outcomes in various therapeutic areas and are underpinned by a deep scientific understanding of chemokine biology.In the most recent fiscal year of 2021, ChemoCentryx reported a revenue of USD 32.22 mn, with an EBITDA loss of USD 126.78 mn, reflecting the company's investment in its research and development for future products.ChemoCentryx aims to expand its product pipeline by developing new therapies that target specific chemokine pathways, with plans for potential launches in the upcoming years. The company is also looking to increase its market footprint in North America and Europe, focusing on expanding into additional therapeutic areas such as oncology. The recent IPO funding will be utilized to support the advancement of these initiatives, ensuring that the company continues to address critical medical needs.

## Funding rounds

- Series D, Mar 22, 2007, $30M — Alta Partners, OrbiMed Advisors, HBM Partners, Gimv, GlaxoSmithKline
- Series C, Aug 24, 2006, $18M — Alta Partners, OrbiMed Advisors, HBM Partners, Gimv, Jennison Associates, Bio-Techne Corporation

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series C, Series D
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C, Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series C, Series D
- Gimv (https://capitalatlas.ai/funds/gimv) — Series C, Series D
- Jennison Associates — Series C
- Bio-Techne Corporation — Series C
- GlaxoSmithKline — Series D